Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial

Abstract

Importance: Patients with hepatocellular carcinoma showing macroscopic vascular invasion have a poor prognosis. Sorafenib is the sole treatment option for these patients, with unsatisfactory response and survival benefit. Combined treatment with transarterial chemoembolization (TACE) plus external beam radiotherapy (RT) has shown promising results for these patients in observational studies.

Objective: To evaluate the efficacy and safety of TACE plus RT compared with sorafenib for patients with hepatocellular carcinoma and macroscopic vascular invasion.

Design, setting, and participants: In this randomized, open-label clinical trial conducted at an academic tertiary care center between July 1, 2013, and October 31, 2016, 90 treatment-naive patients with liver-confined hepatocellular carcinoma showing macroscopic vascular invasion were randomly assigned to receive sorafenib (400 mg twice daily; 45 participants [the sorafenib group]) or TACE (every 6 weeks) plus RT (within 3 weeks after the first TACE, maximum 45 Gy with the fraction size of 2.5 to 3 Gy; 45 participants [the TACE-RT group]).

Main outcomes and measures: The primary end point was the 12-week progression-free survival rate by intention-to-treat analysis. Radiologic response was assessed by independent review according to the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Treatment crossover was permitted after confirming disease progression.

Results: Of the 90 patients (median age, 55 years; range, 33-82 years), 77 were men and 13 were women. All patients had portal vein invasion of hepatocellular carcinoma and Child-Pugh class A liver function. The median maximal tumor diameter was 9.7 cm. Most patients (71 [78.9%]) had multiple lesions. At week 12, the progression-free survival rate was significantly higher in the TACE-RT group than the sorafenib group (86.7% vs 34.3%; P < .001). The TACE-RT group showed a significantly higher radiologic response rate than the sorafenib group at 24 weeks (15 [33.3%] vs 1 [2.2%]; P < .001), a significantly longer median time to progression (31.0 vs 11.7 weeks; P < .001), and significantly longer overall survival (55.0 vs 43.0 weeks; P = .04). Curative surgical resection was conducted for 5 patients (11.1%) in the TACE-RT group owing to downstaging. No patients in the TACE-RT group discontinued treatment owing to hepatic decompensation.

Conclusions and relevance: For patients with advanced hepatocellular carcinoma showing macroscopic vascular invasion, first-line treatment with TACE plus RT was well tolerated and provided an improved progression-free survival, objective response rate, time to progression, and overall survival compared with sorafenib treatment.

Trial registration: clinicaltrials.gov Identifier: NCT01901692.

Figure 1.. Patient Flow Diagram

TACE + RT indicates transarterial chemoembolization plus external beam radiotherapy.

Figure 2.. Estimated Survival Outcomes

A, Progression-free survival at 24 weeks. Progression-free survival rate at 12 weeks: transarterial chemoembolization plus external beam radiotherapy (TACE + RT), 86.7% (95% CI, 77.3%-97.2%); sorafenib, 34.3% (95% CI, 22.6%-52.2%) (hazard ratio [HR], 0.21; 95% CI, 0.12-0.37; log-rank P < .001). B, Median progression-free survival during follow-up (TACE + RT, 30.0 weeks; 95% CI, 22.9-37.1 weeks; sorafenib, 11.3 weeks; 95% CI, 4.4-18.2 weeks) (HR, 0.27; 95% CI, 0.17-0.44; log-rank P < .001). C, Median time to progression during follow-up (TACE + RT, 31.0 weeks; 95% CI, 23.2-38.8 weeks; sorafenib, 11.7 weeks; 95% CI, 5.5-17.9 weeks) (HR, 0.28; 95% CI, 0.17-0.46; log-rank P < .001). D, Median overall survival (TACE + RT, 55.0 weeks; 95% CI, 28.9-81.2 weeks; sorafenib, 43.0 weeks; 95% CI, 25.9-60.1 weeks) (HR, 0.61; 95% CI, 0.38-0.98; log-rank P = .04).